Starling Oncology (STLN) delivered a quarter in which the GAAP headline and the operating results point in opposite directions, and the guidance outweighs both. The company reported a loss of $0.13 per share on revenue of $169.77 million for the September quarter. That missed the consensus loss estimate of $0.07 by 85.7%, while revenue edged past the $168.2 million consensus by 0.9%. Adjusted EBITDA was positive $3.4 million, well above management's $0.5 million to $1.5 million outlook and the second straight positive quarter. The central tension, however, is not the EPS miss. Starling cut its 2026 capitated revenue expectation to roughly $110 million from about $150 million, a target it had held through three prior calls. That cut shrinks the base for the 2027 growth story.

The quality of the miss is less troubling than the headline implies. Most of the $15.7 million net loss came from an $11.6 million loss on debt extinguishment tied to the OrbiMed refinancing. Operating loss narrowed to $3.0 million from $8.1 million a year ago, and gross profit rose 62.1%. Specialty pharmacy remained the engine: revenue grew 44% to $109.3 million, and segment gross margin reached 24.2%, up from 21.6% in Q2 and 19.2% in Q1. Two caveats temper that improvement:

• **Pharmacy margin:** Management acknowledged that the Q3 margin included non-recurring rebates and price movements. It guided toward high-teens margins, while saying the business would still exceed 20% excluding one-time items.
• **Capitated MLR:** The medical loss ratio improved to 81.0% from 85.5% in Q2, beating the roughly 85% management expected. Even so, it is far worse than the 67.8% posted a year ago, and the company expects 85% to 90% in 2027 as new lives onboard.

Beneath the profitability beat, growth is clearly decelerating. Consolidated revenue rose 24.3% year over year, down from 35% in Q2 and 41% in Q1. Fee-for-service revenue fell 21% to $31.3 million despite 9% visit growth, with roughly 40% of that decline attributed to contract restructuring. The bigger problem is Florida. The statewide expansion with three anchor plan partners had already slipped from Q3 to Q4 on the prior call, and it will now not proceed immediately. Management cited an operational and timing issue. As a result:

• **2027 base:** The "100% capitated growth in 2027" framing now implies about $220 million, versus the roughly $300 million framed in Q2. Management declined to reaffirm the higher figure, offering only that there was "no significant departure from consensus."
• **Nevada:** The delegated contract announced in Q2 for a Q4 start was not mentioned among Q4 launches.
• **Full-year revenue:** Guidance narrowed to $650 million to $660 million, trimming the top end.

The forward story is not without support. Oregon went live October 1 as Starling's first delegated capitation contract outside Florida, covering roughly 40,000 Medicare Advantage lives statewide. The Starling Nexus portal is live for 300-plus network practices, with 99.2% utilization management compliance on more than 4,000 Florida authorizations. Part D e-prescribing through Nexus opens an incremental pharmacy channel, and management cited a known 2027 capitation pipeline above $1 billion in annualized spend. Bears have legitimate ammunition on cash, though:

• **Free cash flow:** Year-to-date free cash flow of $20.2 million already exceeds the full-year guide. Yet that guide's top end was cut to $5 million to $10 million, which implies meaningful cash burn in Q4.
• **Working capital:** Year-to-date cash flow leaned heavily on a $39 million increase in accounts payable, partly offset by a $19.8 million inventory build.
• **Liquidity:** Cash fell to $36.9 million from $41.1 million in Q2, the company drew $5 million on a new revolver, and the stockholders' deficit widened to $37.4 million.
• **IRA Phase 2:** The 2027 headwind is modest, at under 5% of pharmacy revenue and under 50 basis points of margin.

The market setup is more complicated than the surprise implies. Investor sentiment improved sharply heading into the report, moving from neutral (0.00) to a solidly positive 0.60. The stock entered earnings at $6.94, up 6.3% since the open after the prior report and about 8.5% above its 200-day moving average of $6.40. Shares sat just 2.7% below the $7.13 inter-earnings high set September 18, which was also a 52-week high, and well above the $5.76 August low. Momentum and AVWAP trend readings were positive. In short, expectations were elevated and the stock was priced near the top of its range just as management lowered the growth trajectory investors had been underwriting.

The bottom line is that Starling's profitability inflection looks real, but the growth narrative took a credible hit. EBITDA, MLR and pharmacy margins all beat, and the GAAP miss is largely a refinancing artifact. However, the roughly 27% cut to 2026 capitated revenue, the softer implied 2027 base, the silence on Nevada and a three-quarter revenue deceleration shift the burden of proof. Investors now need to see Florida and new delegated contracts convert on schedule. Margin normalization toward high teens in pharmacy and 85% to 90% MLR in 2027 also suggests the current quarter may mark a profitability high-water mark rather than a new baseline.